Galderma demonstrates Injectable Aesthetics leadership in medication-driven weight loss with new research and first international consensus-based guidelines Press release
IMCAS 2025: Galderma’s broad presence and new data on recently launched products Restylane® SHAYPE™ and Relfydess® reaffirm its category leadership Press release
Galderma premieres positive interim results demonstrating the efficacy of its Injectable Aesthetics portfolio in addressing facial volume loss as a result of medication-driven weight loss Press release
CHMP recommends approval of Galderma’s nemolizumab for moderate-to-severe atopic dermatitis and prurigo nodularis in the European Union Press release
Galderma’s phase III OLYMPIA 1 data published in JAMA Dermatology demonstrate that nemolizumab improves core signs and symptoms of prurigo nodularis Press release
Celebrating 25 years of Sculptra®: new data and recent approval in China cements Galderma’s leadership in regenerative biostimulation Press release
ASDS 2024: new phase III READY-4 data demonstrate long-term safety and efficacy of Galderma’s RelabotulinumtoxinA (Relfydess™) Press release
EADV 2024 Late breaking news sessions: new Galderma data demonstrating nemolizumab’s long-term efficacy and safety in atopic dermatitis and durability in prurigo nodularis to be shared during three oral presentations Press release
